tbuckley/cabot-search huggingface dataset:
Clinical characteristics and outcomes of 57 cases with incidental pulmonary embolism
Authors: Xiaomao Xu, Yulin An, Min Zhang, Chen Wang
Journal: BMJ (2016)

Objective
To identify the clinical characteristics and outcomes of incidental pulmonary embolism (IPE).


Methods
Clinical data of patients who took an examination of contrast enhanced computed tomographic (CECT) from January 2004 to March 2014 were retrospectively reviewed. Clinical presentation and outcomes of 75 patients with IPE were evaluated. The information including predisposing factors, clinical picture, imaging, Wells score and classification of PE was recorded.


Results
A total of 78 425 patients underwent CECT examinations, among whom 57 cases of IPE (30 men and 27 women) with median age of 66.6 years were identified. The incidence rate of IPE was 0.07% and most of the patients were diagnosed in chest CECT. Forty patients (70.2%) had malignancy as common comorbidity and most of them were lung cancer and gastrointestinal cancer. Thirty five patients (61.4%) had respiratory symptoms such as dyspnea, cough and expectoration, and there were statistic significance difference of dyspnea (38.6% vs. 62.1%, χ2=10.0, P=0.002) and palpitation (3.5% vs. 15.8%, χ2=5.88, P=0.015%) between IPE and suspected pulmonary embolism (SPE) patients. The Wells score of 43 patients (75.4%) was less than 2. Compared to SPE, the classification of PE in 55 IPF patients (96.5%) were low risk (χ2=22.86, P=0.000). Only 26 patients (45.6%) received anticoagulation therapy in IPE group. There were 9 patients (15.8%) of IPE died within 1 year and most of them died from cancer; while 10 patients (4.9%) died in SPE patients (χ2=7.75, P=0.005).


Conclusions
IPE is more prevalent in patient with malignancy. The clinical presentation is always confused by common comorbidity leading to fail to diagnose. The classification of IPE is low risk, but it increases the mortality of cancer patients within 1 year.


Key words: 
Pulmonary embolism; Tomography, X-Ray computed; Diagnosis
Rate of complete and durable responses of intralesional therapy with talimogene laherparepvec for stage IIIB-IVM1a melanoma and association with tumor load.
Authors: Emma H.A. Stahlie, Viola Franke, Charlotte L. Zuur, Willem M.C. Klop, Bernies Van Der Hiel, Bart A. Van De Wiel, Michel W.J.M. Wouters, Yvonne Schrage, Winan J. van Houdt, Alexander Christopher Jonathan Van Akkooi
Journal: Journal of Clinical Oncology (2020)

e22089 Background: Talimogene laherparepvec (T-VEC) is a genetically modified herpes simplex type 1 virus, which is used as an oncolytic immunotherapy in stage IIIB-IVM1a melanoma patients. It is known to be an effective therapy for injectable cutaneous, subcutaneous and nodal melanoma lesions, as approved by the European Medicines Agency (EMA). Combination therapy is not yet approved by EMA pending the results of the phase 3 Masterkey-265 trial. The objective of the current study was to identify prognostic factors for achieving a complete response (CR) that can be used to select patients for treatment with T-VEC monotherapy. Methods: Patients with stage IIIB-IVM1a melanoma, treated with T-VEC at the Netherlands Cancer Institute between 2016-12 and 2019-05 with a follow-up time &gt; 6 months, were included. Data was collected on baseline characteristics, responses and adverse events (AEs). Durable response rate (DRR) was defined as the percent of patients with a CR or partial response (PR) maintained continuously &gt; 6 months. Univariable analyses were conducted and a prediction model was developed to identify prognostic factors associated with complete response. Results: For this study, a total of 71 patients were included with a median follow-up of 16.1 months. The median age was 70 years (range: 35-90). As best response, 47 patients (66%) had a CR and 10 patients (14%) had a PR, resulting in an overall response rate of 80%. Twenty-one patients (30%) stopped treatment because of progressive disease and sixteen patients (23%) developed a recurrence during follow-up after achieving a PR or CR. Median duration of CR was 11 months. The durable response rate was 42%. Grade 1-2 AEs occurred in almost every patient. Tumor size, type of metastases, previous treatment with systemic therapy and stage (8 Th AJCC) were independent prognostic factors for achieving a CR and for progression-free survival. Achieving a CR was associated with a reduced risk of death. The prediction model includes tumor size, type of metastases (only cutaneous vs. subcutaneous (+/- cutaneous) vs. nodal (+/- cutaneous/subcutaneous)) and number of lesions as predictors. Conclusions: This study shows that intralesional T-VEC monotherapy for stage IIIB-IVM1a melanoma is able to achieve high complete and durable response rates. The prediction model shows that use of T-VEC in patients with less tumor burden is associated with better outcomes, suggesting T-VEC should perhaps be used earlier in the course of the disease.
Recurrence rates and relapse-free survival for patients with completely resected melanoma: Contemporary experience.
Authors: Asim Amin, Sally Jeanne Trufan, Brittany Neelands, Nicole Lee Gower, Melisa Pasli, Richard L. White
Journal: Journal of Clinical Oncology (2020)

e22080 Background: An estimated 100,000 new diagnoses of malignant melanoma are expected in 2020. Systemic treatment with immune checkpoint inhibitors (ICIs) and targeted therapy with BRAF/MEK inhibitors have impacted the natural history for resectable and unresectable/advanced disease. ICIs and the combination of dabrafenib plus trametinib have been shown to decrease the risk of recurrence. Eligibility to receive adjuvant treatment has been based on melanoma specific survival (MSS) reported by AJCC. Romano et al. (JCO 2010) have previously reported their single institution 5yr data from 1998-2004 for stage IIIa/b/c melanoma relapse free survival (RFS) to be 63%, 32% and 11% respectively. Per the AJCC 8 th edition, the 5yr MSS for stage IIIa/b/c is 93%, 83% and 69% respectively. We report our single institution data for recurrence rate (RR) and RFS. Methods: Our prospective database was queried for patients with stage IIb/c, IIIa/b/c (per AJCC 7 th edition) from 2005 to 2019. Time to recurrence and relapse free survival were calculated using time from surgery date to chart review. Results: 529 patients with stage IIb/c, IIIa/b/c patients were identified. The cohort was 63% male and 98% white, with a median age of 60 (IQR 48-70). The distribution of disease stage was: IIb, 27%; IIc, 10%; IIIa, 23%; IIIb, 22%; IIIc, 17%. The median time to recurrence for all patients was 1.15yrs (IQR 0.57-2.3). The overall RR was 36%. RR by stage were: IIb, 28%; IIc, 36%; IIIa, 26%; IIIb, 47%; IIIc, 46%. Recurrence most often was associated with a primary lesion on the trunk (36%), followed by head/neck (26%), lower extremity (23%) and upper extremity (15%). Distant recurrence accounted for 54% of all first recurrences, followed by regional (34%) and local (12%). The 2yr and 5yr RFS were significantly different by stage (p &lt; 0.0001) (Table). Conclusions: 5yr RFS for stage IIIa disease in our study is considerably higher compared to the Romano et al. data (71% vs 63%). The 5yr MSS has improved from 78% to 93% (AJCC 7 th vs 8 th edition). Our group has demonstrated improvement in RFS when compared to historical reports suggesting further investigation is needed into IIIa patients most likely to benefit from adjuvant therapy. [Table: see text]
Effect of hydrogen peroxide on the sustained release of <sup>99m</sup>Tc-labeled cytarabine in melanoma of C57 mice by ECT imaging pharmacology.
Authors: Yan Han, Qiang Fu, Baofa Yu
Journal: Journal of Clinical Oncology (2020)

e15569 Background: To investigate the residence time of 99m Tc-labeled cytarabine in mouse tumors under ECT imaging. Methods: The subcutaneous solid tumor model of mice was established by injection of melanoma cell suspension into the left forelimb of C57 mice. The tumor-bearing mice were divided into treatment group and control group when the longest diameter of the tumor was 5-8 mm. Group 3 only. The mice in the control group were given intratumoral injection of 0.1 ml of 99m Tc-labeled cytarabine solution, and the mice in the treatment group were given intratumoral injection 0.1 ml 99m Tc labeled cytarabine combined with hydrogen peroxide solution at 0.25 h, 0.5 h, 1 h. After 2 hours and 19 hours of administration, the radioactivity intensity values were observed by SPECT Apx-409 ECT phenomenon equipment. Results: The T/W values of ECT imaging in 3 mice in the treatment group were higher than those in the control group at 0.25 h, 0.5 h, 1 h, 2 h and 19 h. The T/W values of ECT imaging decreased in the treatment group at different time points. The amplitude was lower, and the T/W values in each period were higher than those in the control group. Conclusions: The sustained release agent hydrogen peroxide can significantly increase the residence time of 99m Tc-labeled cytarabine in the tumor. It is speculated that hydrogen peroxide has a positive effect on prolonging the drug action time of cytarabine and improving the effect of killing tumor cells. It showed that H2O2 can hold the Ara-C for a long time in tumor.
Effect of occupational therapy with international classification of functioning, disability and health model on activities of daily living of stroke patients in communities
Authors: Hanping Xu, Lan Tang, Liqing Zhou, Qi Qi
Journal: BMJ (2016)

将42例社区脑卒中患者随机分为国际功能、残疾和健康分类(ICF)模式训练(观察组)及传统模式训练(对照组)，各21例，行作业训练3个月，观察作业训练前、后两组患者改良Barthel指数、Fugl－Meyer运动功能评定量表(FMA)、功能综合评定量表(FCA)、SF－36健康调查量表(SF－36)的评分。训练前、后改良Barthel指数、FMA、FCA和SF－36评分观察组分别为(53.1±12.6)与(62.4±13.7)分、(40.9±14.1)与(46.7±14.6)分、(49.3±11.1)与(58.2±10.4)分、(84.9±17.2)与(100.2±16.6)分，对照组分别为(46.7±13.0)与(51.4±12.8)分、(36.8±14.4)与(42.3±13.8)分、(45.9±11.6)与(50.9±11.8)分、(83.0±22.9)与(91.8±22.9)分，训练后评分均显著增高(均P<0.01)；训练后观察组改良Barthel及FCA评分高于对照组(均P<0.05)。提示ICF理念下的作业训练模式对脑卒中患者日常生活活动能力和社会适应性的提高优于传统作业训练。
Occupational security awareness and occupational protection skills among community nurses
Authors: 吴兰笛, 韩卫丽
Journal: BMJ (2007)

目的 探讨影响广州社区护士职业安全的相关因素及提高服务意识和培训职业保护能力的有效措施.方法 采用问卷的方法调查分析广州市1702名社区护士对影响社区护士职业安全相关因素的认识以及运用职业防护技能的情况.结果 社区护士自我评估,21.3%(362/1702)完全了解职业安全的概念;12.0%(204/1702)完全了解职业防护的内容;12.3%(209/1702)完全掌握部分职业防护技能.结论 社区护士职业安全意识普遍较弱,职业防护技能总体较差,应结合开展社区安全护理的工作特点制订相关管理制度、操作流程和突发事件应急预案对社区护士进行培训。
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent
Authors: Alessio Mazzoni, Lorenzo Salvati, Laura Maggi, Manuela Capone, Anna Vanni, Michele Spinicci, Jessica Mencarini, Roberto Caporale, Benedetta Peruzzi, Alberto Antonelli, Michele Trotta, Lorenzo Zammarchi, Luca Ciani, Leonardo Gori, Chiara Lazzeri, Andrea Matucci, Alessandra Vultaggio, Oliviero Rossi, Fabio Almerigogna, Paola Parronchi, Paolo Fontanari, Federico Lavorini, Adriano Peris, Gian Maria Rossolini, Alessandro Bartoloni, Sergio Romagnani, Francesco Liotta, Francesco Annunziato, Lorenzo Cosmi
Journal: Journal of Clinical Investigation (2020)

BACKGROUND. Coronavirus disease 19 (COVID-19) is an emerging infectious disease caused by SARS-CoV-2. Antiviral immune response is crucial to achieve pathogen clearance; however, in some patients an excessive and aberrant host immune response can lead to an acute respiratory distress syndrome. The comprehension of the mechanisms that regulate pathogen elimination, immunity, and pathology is essential to better characterize disease progression and widen the spectrum of therapeutic options.
晚期流产的病因和处理
Authors: 范建霞
Journal: BMJ (2011)

晚期流产并不常发生,但对产妇心理打击巨大,应引起重视.胎儿发育异常,包括染色体异常、母体子宫发育异常、宫颈机能不全、免疫因素、感染、血栓形成等是发生晚期流产的主要原因,但确切原因往往难以确定.系统病史询问及体格检查可协助寻找病因,结合实验室检查,可对病因进行相应治疗。
Genomic aberration of chromatin regulatory BAF complex as predictive biomarker for immunotherapy in gastrointestinal adenocarcinoma.
Authors: Changsong QI, Sai Ge, Zhi Peng, Xiaotian Zhang, Yu Xu, Guoqiang Wang, Yuezong Bai, Lin Shen
Journal: Journal of Clinical Oncology (2020)

4035 Background: SNF/SWI, a large ATP-dependent chromatin remodeling complex, is required for transcriptional activation of genes normally repressed by chromatin, and critical to tumor initiation and progression. Here, we analyzed the predictive utility of the mutations of the SNF/SWI members involved in BAF and PBAF complexes, and sought to explore the potential mechanisms. Methods: Clinical, genomic, transcriptional, and immunohistochemical data from immunotherapeutic cohort (MSKCC, n=185), Cancer Cell Line Encyclopedia (CCLE, n=92), The Cancer Genome Atlas (TCGA, n=925), and 3D Medicines database (3DMed, n=1812) were analyzed to explore the predictive effect of genomic aberration of BAF complex on the benefit from immunotherapy in patients with gastrointestinal adenocarcinoma. Results: In the MSKCC cohort involving 185 patients with gastrointestinal adenocarcinoma, the mutation of any member involved in BAF complex ( ARID1A, ARID1B, SMARCA4, SMARCB1, and SMARCD1) was significantly associated with prolonged OS of ICI treatment (HR 0.53, 95%CI 0.31-0.90, P=0.019), instead of the mutations of PBAF members including PBRM1 and ARID2. In addition, BAF mutation was not linked with better prognosis in TCGA database, indicating its predictive, not prognostic efficacy of immunotherapy. BAF-mutated samples exhibited higher tumour mutational burden (TMB, P&lt;0.05, Table), and increased mRNA expression of immune-related genes including chemokines and granzyme A. In the 3DMed cohort where tumour samples received both genomic sequencing and PD-L1 immunohistochemical staining, BAF mutation was associated with higher PD-L1 positive rate in tumour cells (P&lt;0.05, Table). Conclusions: Genomic aberration of members in chromatin regulatory BAF complex may serve as a predictive, not prognostic biomarker of ICI benefit in patients with gastrointestinal adenocarcinoma, partially underlying the mechanisms including higher mutational burden, transcription of immune-related genes, and protein-level PD-L1 expression. [Table: see text]
High intratumoral tryptophan metabolism is a poor predictor of response to pembrolizumab (pembro) in metastatic melanoma (MM): Results from a prospective trial using baseline C11-labeled alpha-methyl tryptophan (C11-AMT) PET imaging for response prediction.
Authors: Jorge D. Oldan, David W. Ollila, Ben C. Giglio, Eric Smith, Deeanna M. Bouchard, Marija Ivanovic, Yueh Z. Lee, Frances A. Collichio, Michael O. Meyers, Diana E. Wallack, Amir H. Khandani, Amber Abernathy-Leinwand, Patricia K. Long, Jennifer Ashley Ezzell, Dimitri G. Trembath, Zibo Li, Terence Z. Wong, Stergios J. Moschos
Journal: Journal of Clinical Oncology (2020)

3556 Background: Molecular imaging of metabolic pathways critical for effector T cell response other than glucose could predict response to PD1 inhibitors. We have previously shown that high expression of tryptophan metabolic pathway enzymes in stage III/IV melanoma correlates with reduced abundance of tumor-infiltrating lymphocytes (TILs, ASCO 2019, e21014). Here we investigated C11-AMT, a PET tracer that images tryptophan metabolism, as a predictor of response to pembro in patients (pts) with PD1 inhibitor-naïve MM. Methods: In this trial (NCT03089606) pts must have had measurable MM by RECIST, have undergone IV contrast CT, FDG-PET, and C11-AMT PET scan (30-40 min dynamic imaging), plus a mandatory tumor biopsy prior to pembro treatment. Results: 21 pts (16 males; 15 stage IV; median age 61) had all 3 baseline scans and evaluable research biopsies. 13 pts were non-progressors (CR = 4, PR = 6, and SD = 3). At a median f/u of 13.7 mons (2.8-25.1+), 6 pts are dead from MM, 11 are alive without MM and 4 are alive with MM. 46 tumor lesions were assessed by all 3 scans. Of the pts with tumor lesion, C11-AMT PET SUV max &lt; 7 and skewness &lt; +0.3 of the tumor lesion with the highest C11-AMT SUV max was associated with non-progression by RECIST (SUV max &lt; 7/skewness &lt; +0.3 in progressors vs. non-progressors; Fisher’s 2-tail test p= 0.055). The corresponding association between baseline FDG-PET (SUV max &lt; 14 and skewness &lt; +0.3) with treatment response was insignificant ( p= 0.08). There was a weak (Spearman ρ= 0.33) but significant correlation ( p= 0.001) in SUV max between FDG-PET and C11-AMT among the 46 tumors analyzed. There was no significant correlation between melanoma-specific expression of the tryptophan- (TPH1, TPH2, IDO1, TDO2, LAT1) and glucose-metabolizing enzymes (GLUT1, HK1, HK3) by immunohistochemistry. Response to pembro trends to associate with present TILs (Fisher’s p= 0.087). Conclusions: Baseline C11-AMT PET imaging using simple radiomics measures (highest metabolic activity, SUVmax, and tumor heterogeneity, skewness) may better predict clinical benefit from pembro in MM than FDG PET. Variability in C11-AMT’s SUV max cannot be solely explained by FDG-PET’s SUV max , suggesting that these two imaging modalities may provide complementary information about intratumoral metabolic dysregulation that may relate with pembro response. Texture analysis using LifeX v4.0 will be presented at the meeting. Clinical trial information: NCT03089606 .
Risk factors and diagnosis of cognitive dysfunction after coronary artery bypass grafting
Authors: 陈明盈, 毕齐
Journal: BMJ (2010)

冠状动脉旁路移植术(coronary artery bypass graft,CABG)是目前心脏外科治疗冠状动脉粥样硬化性心脏病(冠心病)常用和有效的方法之一,其术包括体外循环下冠状动脉旁路移植术(on-pump CABG)和非体外循环下冠状动脉旁路移植术(off-pump CABG).随着心脏外科手术技术的不断进步,off-pump CABG在临床上已经成为冠心病外科治疗的发展趋势。
ACUFOCIN: Randomized clinical trial of ACUpuncture plus standard care versus standard care alone FOr Chemotherapy Induced peripheral Neuropathy (CIPN).
Authors: Andrew M. Wardley, David Ryder, Vivek Misra, Peter S Hall, Peter Mackereth, Jacqui Stringer
Journal: Journal of Clinical Oncology (2020)

12003 Background: CIPN is a dose limiting toxicity, and a major clinical challenge. This study aims to explore the use of acupuncture with standard care (Acu +SC) against SC alone, to reduce symptoms of CIPN. Methods: A phase II, randomised, parallel group design was used to investigate the effectiveness of a 10 week course of acupuncture to manage CIPN. Patients experiencing CIPN ≥ Grade II (CTCAE v4.03), recording a ‘Most Troublesome’ CIPN symptom score of ≥ 3 using the "Measure Yourself Medical Outcome Profile" (MYMOP 2), were randomised (1:1) to either Acu+SC or SC alone. The primary end-point was a ≥ 2 point improvement in MYMOP2 score at week 10 (logistic regression adjusted for stratification factors and baseline MYMOP2 score). The necessary sample size was 100 patients;120 were randomised to allow for attrition (90% power; 10% one-sided alpha), for a hypothesised improvement in success proportions from 30% to 55%. Results: 120 patients were randomised to ACUFOCIN; diagnosis: breast 61 (51%), multiple myeloma 9 (8%), GI 48 (40%), gynaecological 2 (2%). MYMOP2 score for most troubling CIPN symptom at baseline: 3-4 33 (28%), 5-6 87 (73%). CTCAE CIPN at baseline; grade II 103 (86%), grade III 17 (14%). Baseline characteristics were balanced between arms. Primary outcome data were available for 108 participants with 36/54 (67%) successes in the Acu+SC arm compared to 18/55 (33%) in the SC arm. Adjusted success odds ratio was 4.3 (95% CI 1.9-9.6; p &lt; 0.001; Acu+SC vs SC). Additionally, 27/53 (51%) participants achieved a CIPN success (grade ≤ I) in the Acu+SC arm compared to 4/56 (7%) in the SC arm with adjusted odds ratio 13.1 (95% CI 4.1-41.7; p &lt; 0.001; Acu+SC vs SC). Significant reduction in week 10 pain score; mean difference (SC+Acu – SC alone) -1.45 with 95% CI (-2.25, -0.65) after adjustment for week 1 pain, breast cancer diagnosis and treatment complete status. (note pain on a 0-10 scale). Significant increase in the EORTC QLQ-C30 summary score; mean difference (SC+Acu – SC alone) 9.51 with 95% CI (5.01, 14.02) after adjustment for the baseline score, breast cancer diagnosis and treatment complete status. (note summary score on a 0-100 scale). Significant effects seen at week 10 are also present at week 6. The week 6 effect estimates are consistently less than the week 10 effects (but not usually statistically significantly so). Conclusions: In this patient cohort, a 10 week course of acupuncture significantly improved symptoms of CIPN. These results support further investigation within a phase III trial. Clinical trial information: NCT02275403 .
传染性非典型肺炎期间咨询热线信息分析
Authors: 马晓翔, 解顺堂, 杨海
Journal: BMJ (2005)

为了解市民对突发疫情心理承受能力及关注热点,研究2003年传染性非典型肺炎(非典)流行期间咨询热线信息的变化规律.信息来自我中心2003年4月19日至6月30日非典咨询热线值班记录。
Molecular profiles and immune checkpoint inhibitor-related biomarkers analysis in advanced cervical cancer.
Authors: Qin Xu, Chuanben Chen, Yang Sun, Yibin Lin, Jing Liu, Li Li, Lianpeng Chang, Yaping Xu, Lifeng Li, Bin Huang, Chenchen Zhu
Journal: Journal of Clinical Oncology (2020)

e18003 Background: Treatment options for advanced cervical cancer (ACC) are limited and patients experiencing recurrence after first-line chemotherapy and bevacizumab have a poor prognosis. Checkpoint inhibitors targeting the PD-1/PD-L1 are promising treatment option. However, related genomic biomarker study is rare reported in ACC. Methods: We prospectively enrolled 102 pts with ACC. Tumor and plasma samples were obtained to analysis genomic profiles. DNA was sequenced by target-capture deep sequencing with the pan-cancer panel. TMB of tissue (tTMB) and blood (bTMB) analysis interrogated single nucleotide variants, small insertion and deletion. PD-L1 expression was evaluated in tumor specimens by immunohistochemistry (IHC) using a combined-positive-score (CPS) cutoff of ≥1. Results: The median age of enrolled pts was 63 yrs, and most (84.3 %, 86/102 pts) weresquamous carcinoma. A total of 93 tissues and 96 plasma were collected from 102 pts. The most frequently mutated genes were PIK3CA (40.9%, 38/93 pts), KMT2D (35.5%, 33/93 pts), and KMT2C (28.0%, 26/93 pts) in tissues. 80% (77/96 pts) of plasma was detected positive, with PIK3CA (23.4%, 18/77 pts), KMT2D (20.8%, 16/77 pts), KMT2C (20.8%, 17/77 pts) mutant frequently. Among 87 pts with paired samples, at least a tumor-derived mutation was detected in 35 (40.2%)plasma. Median of tTMB was 11.9 mut/Mb, and 45% pts were TMB-H. Significant correlation was found between tTMB and bTMB (Pearson r = 0.39, P = 0.001). Higher tTMB was identified in KMT2D- or KMT2C-mut pts (P = 0.002 or P = 0.01, respectively). tTMB showed no relation with clinic characteristics, including pathological subtype, FIGO stage, and status of distant metastasis. PD-L1 expression (CPS≥1) was identified in 53 pts (93 %, 53/57) and mutually independent with TMB status. Conclusions: Molecular profiles and TMB in plama showed high consistence with that in tissue. Prospective clinical trial is ongoing to determine the genomic biomarkers and the PD-L1 expression as predictive factors for the ICI efficacy in ACC (ChiCTR1900023015).
Congenital nephrotic syndrome combined with skull dysplasia: case report and literature review
Authors: Jing Liu, Rui-hong Tang, Zhi-chun Feng
Journal: BMJ (2008)

A case of congenital nephrotic syndrome (CNS) combined with skull dysplasia was confirmed based on clinical findings, laboratory examination and skull CT scan. Hereditary features, clinical manifestations, treatment and prognosis of CNS were reported in this paper after literatm'e review.

Key words: 
Nephrotic syndrome;  Bone diseases, development
痰标本检出耐碳青霉烯类抗生素肺炎克雷伯菌二例
Authors: 赵书平, 姜梅杰
Journal: BMJ (2010)

例1 男,出生10 d.早产后发生肺炎并窒息,体温39.5 ℃,于2006年6月入院治疗.血白细胞1.6×109/L,分类中性粒细胞0.76,淋巴细胞0.24,胸部X线示双肺纹理明显增多,临床诊断为新生儿肺炎。